The short version of Angiotensin IV analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
=== Turnover and cell renewal === Cell division occurs predominantly in the basal layer, with cells migrating coronally and superficially. The turnover rate is slower than the junctional epithelium but faster than fully keratinized gingival epithelium.
Lemna can be farmed organically, with nutrients being supplied from a variety of sources, for example human urine, cattle manure, pig waste, biogas plant slurry, or other organic matter in slurry form. Because of the rapid growth of Lemna, daily harvesting is necessary to achieve optimal yields. Harvesting is done such that less than 1 kg/m2 of duckweed remains. Under optimal conditions, a duckweed farm can produce 10 to 30 tons of dried duckweed per hectare per year.
== History == Natural enzymes catalyze chemical reactions with high selectivity and efficiency. Catalysis occurs in the enzyme's active site, where substrates bind near functional groups, enabling proximity effects. Artificial enzymes mimic this by combining substrate-binding sites (e.g., cyclodextrins, crown ethers, or calixarenes) with catalytic groups in small molecules. Advances include artificial enzymes based on amino acids or peptides, such as scaffolded histidine residues mimicking metalloproteins like hemocyanin, tyrosinase, and catechol oxidase. Computational design using tools like Rosetta has enabled de novo creation of artificial enzymes. In 2014, enzymes were created from non-natural molecules. A 2016 book chapter discussed future directions in artificial enzymes.
The three substrates of this enzyme are phenylacetaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are phenylacetic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is phenylacetaldehyde:NAD+ oxidoreductase. This enzyme participates in phenylalanine metabolism and styrene degradation.
Sources: en.wikipedia.org
Thioesters exhibit electrosteric repulsive forces due to amine functional groups and their size, which prevents aggregation. These electrostatic repulsive forces are weakened by counterions in solution, such as Ca2+ found in seawater. Ca2+ ions are naturally found in seawater due to the weathering of calcareous rocks, and allow for dissolution of the oxide-coated particle at low electrolyte concentrations. This leads to the aggregation of silver nanoparticles onto thioesters in seawater. When aggregation occurs, the silver nanoparticles lose microbial toxicity, but have greater exposure in the environment for larger organisms. These effects have not been completely identified, but may be hazardous to an organism's health via biological magnification.
== Chemistry == Meclizine is a first-generation antihistamine (nonselective H1 antagonist) of the piperazine class. It is structurally and pharmacologically similar to buclizine, cyclizine, and hydroxyzine.
In the UK, a House of Commons Select Committee on Environment, Food and Rural Affairs report on the horse meat incident was not critical of UK or Irish producers. It expressed concern that horsemeat contamination resulted from fraud and other criminal activity across the EU. Chair of the Committee, Anne McIntosh MP, said: "The evidence suggests a complex network of companies trading in and mislabelling beef or beef products which is fraudulent and illegal." The second major UK report on the horse meat incident was conducted by Professor Chris Elliott, the Director of the Institute for Global Food Security at Queen's University Belfast. In his independent report, he argues that food crime was at the heart of the horsemeat incident and makes a range of suggestions for how this could be tackled. "Industry, government and enforcement agencies should, as a precautionary principle, always put the needs of consumers above all other considerations, and this means giving food safety and food crime prevention—i.e. the deterrence of dishonest behaviour—absolute priority over other objectives."
Sources: en.wikipedia.org
== Interactions == No interaction studies have been conducted because the drug does not reach the bloodstream and the liver. It is theorised that drugs interfering with matrix metalloproteinases, such as tetracyclines, anthracyclines, quinolones, and anthraquinone derivatives, could reduce the efficacy of the collagenases, but no clinical evidence for such an interaction has been observed.
== Therapeutic use == In people with kidney failure, requiring dialysis, a cimino fistula is often deliberately created in the arm by means of a short day surgery in order to permit easier withdrawal of blood for hemodialysis. As a radical treatment for portal hypertension, surgical creation of a portacaval fistula produces an anastomosis between the hepatic portal vein and the inferior vena cava across the omental foramen (of Winslow). This spares the portal venous system from high pressure which can cause esophageal varices, caput medusae, and hemorrhoids.
== Lipid catabolism == Once the chylomicrons (or other lipoproteins) travel through the tissues, these particles will be broken down by lipoprotein lipase in the luminal surface of endothelial cells in capillaries to release triglycerides. Triglycerides are broken down into fatty acids and glycerol before entering cells and remaining cholesterol will again travel through the blood to the liver.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.